Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
September 24, 2018 09:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several...
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
September 24, 2018 08:00 ET
|
Altimmune, Inc.
New funding will allow examination of mucosal immune response and additional vaccine characterization GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a...
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine
September 04, 2018 08:00 ET
|
Altimmune, Inc.
Six-month data demonstrates: A statistically superior mucosal immune response providing a first line of defense against infection;A durable serum immune response at six months compared to over 50%...
Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study
August 31, 2018 08:00 ET
|
Altimmune, Inc.
Studies funded by BARDA GAITHERSBURG, Md., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase...
Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update
August 14, 2018 16:01 ET
|
Altimmune, Inc.
Conference call and webcast scheduled for tomorrow, August 15, 2018, at 8:30am ET GAITHERSBURG, Md., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
Altimmune to Announce Second Quarter 2018 Financial Results on August 15
August 07, 2018 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the...
Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors
July 12, 2018 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has...
Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer
July 10, 2018 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 10, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has appointed Mitchel...
Altimmune Restructures Financing Agreement
June 22, 2018 16:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has...
Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 15, 2018 16:01 ET
|
Altimmune, Inc.
Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET GAITHERSBURG, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage...